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Abstract
Using an immunohistochemical tech-
nique, we have studied the distribution of
kynuneric acid (KYNA) and 3-hydroxyan-
thranilic acid (3-HAA) in a rat brain injury
model (trauma). The study was carried out
inducing a cerebral ablation of the frontal
motor cortex. Two mouse monoclonal spe-
cific antibodies previously developed by
our group directed against KYNA and 3-
HAA were used. In control animals (sham-
operated), the expression of both KYNA
and 3-HAA was not observed. In animals in
which the ablation was performed, the
highest number of immunoreactive cells
containing KYNA or 3-HAA was observed
in the region surrounding the lesion and the
number of these cells decreased moving
away from the lesion. KYNA and 3-HAA
were also observed in the white matter
(ipsilateral side) located close to the injured
region and in some cells placed in the white
matter of the contralateral side. The distri-
bution of KYNA and 3-HAA perfectly
matched with the peripheral injured
regions. The results found were identical
independently of the perfusion date of ani-
mals (17, 30 or 54 days after brain injury).
For the first time, the presence of KYNA
and 3-HAA has been described in a rat trau-
ma model. Moreover, by using a double
immunocytochemistry protocol, it has been
demonstrated that both metabolites were
located in astrocytes. The findings
observed suggest that, in cerebral trauma,
KYNA and 3-HAA are involved in tissue
damage and that these compounds could
act, respectively, as a neuroprotector and a
neurotoxic. This means that, in trauma, a
counterbalance occurs and that a regulation
of the indoleamine 2,3 dioxygenase (IDO)
pathway could be required after a brain
injury in order to decrease the deleterious
effects of ending metabolites (the neurotox-
ic picolinic acid). Moreover, the localiza-
tion of KYNA and 3-HAA in the contralat-
eral side of the lesion suggests that the IDO
pathway is also involved in the sprouting
and pathfinding that follows a traumatic
brain injury. 
Introduction 
Traumatic injuries are major health and
socioeconomic problems affecting nowa-
days our societies.1,2 Traumatic brain injury
(trauma) is the leading cause of loss of
human potential around the world, and
especially in low and middle income coun-
tries.3 Severe lesions of motor cortex pro-
duce devastating effects, affecting volun-
tary movements.4 Almost one out of every
ten deaths in the world were caused from
injuries in 2010, higher than malaria, tuber-
culosis and immune deficiency syndrome
combined together.5,6
Trauma occurring mechanisms are very
similar to those occurring in neurodegener-
ative and ischemic processes. Ischemic
stroke is characterized by glutamate excito-
toxicity, excessive ROS production and
inflammation,7-10 these processes also occur
in traumatic brain injury.11 In stroke,
indoleamine 2,3-dioxygenase (IDO) and
nitric oxide (NO) pathways are activated
and several intermediate metabolites of the
IDO pathway such as kynurenic acid
(KYNA) and 3-hydroxyanthranilic acid (3-
HAA) are overexpressed during ischemic
stroke.8-10 KYNA, a tryptophan catabolite,
is mainly synthesized by astrocytes,12,13 acts
as a scavenger in these cells14 and, in
ischemia, exerts a neuroprotective role
against the neuronal loss.15 By contrast, 3-
HAA (another tryptophan catabolite) exerts
a cytotoxic effect.16-18 In fact, 3-HAA
inhibits mitochondria respiration, promotes
oxidative damage on proteins and induces
apoptosis.10,18-22
To our knowledge, the neuroanatomical
distribution of the immunoreactive struc-
tures containing KYNA or 3-HAA in the
mammalian central nervous system has
been studied in an ischemic stroke model
only and, in this model, the involvement of
the IDO pathway has been demonstrated.8-10
Since mechanisms occurring in trauma are
very similar to those appearing in stroke,23-
24 our main aim is to study in a trauma
model (ablation of the motor cortex) the
presence / overexpression of markers
(KYNA, 3-HAA) of the IDO pathway. This
pathway has been implicated in some
pathological mechanisms (e.g., inflamma-
tion).25-28 Thus, the presence, absence or
overexpression of these molecules belong-
ing to the IDO pathway will serve to
increase our knowledge on the underlying
mechanisms occurring during traumatic
processes (that is, the involvement of the
IDO pathway in brain trauma) and to sug-
gest possible therapeutic strategies for the
treatment of brain trauma.
Materials and Methods
Animals and experimental groups
Twenty-four adult male Wistar rats
(Charles River, 200-220 g at arrival) were
used. Animals were housed under standard-
ized conditions of light and temperature for
7 days before the experiments started.
Animals were fed ad libitum, except when
the paw-reaching-for-food task was carried
out. For this procedure, animals were main-
tained at 86-88% of their initial ad libitum
weight.4,29 The experimental procedure of
this work was performed under the guide-
lines of the legal and ethics recommenda-
tions of French, Spanish and European laws
(2010/63/EU). Moreover, this study was
approved by the research commission of the
University of Salamanca (Spain).
Animals were divided into two groups:
operated (surgical procedure with ablation
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of the cortex, n=12) and “sham-operated”
animals (surgical procedure without abla-
tion of the cortex, n=12). Animals of both
groups were perfused at 17, 30 and 54 days
after the surgical intervention.
Ablation of frontal motor cortex
The ablation of deeply anesthetized ani-
mals was conducted by aspiration of the
motor cortex. Thus, ablation of the con-
tralateral cortex to the preferred paw was
conducted by using a stereotaxic apparatus
taking as reference the Bregma suture in
order to conduct the same lesion to all ani-
mals (Figure 1). Sham-operated animals
were anesthetized, according to their
weights, and operated like the animals of
the operated group (crania, meninges), but
no ablation of the cortex was conducted. As
previously described, lesion effectiveness
was verified 7 days after the operation.29
Immunocytochemical study
Once the model was carried out and the
animals perfused (17, 30 or 54 days), an
immunocytochemical study was performed.
As previously reported,8-10,29 animals were
deeply anaesthetized with Equithesin and
perfused with paraformaldehyde (PAF)
(4%); brains were dissected out after decap-
itation, post-fixed in 4% of PAF for 16 h
and cryoprotected in sucrose. Using a freez-
ing microtome, 40-45 µm-thick brain coro-
nal sections were obtained and processed
for immunocytochemistry.8-10 As previously
described8-10,30,31 and in order to inactivate
the endogenous peroxidases, sections were
pre-incubated in a mixture solution of
methanol/H2O2 (2v/1v) for 30 min. Then,
sections were washed three times with PBS
for 30 min and pre-incubated in a PBS solu-
tion containing 0.3% Triton X-100 and sup-
plemented with 1% of normal horse serum
(mixture solution) for 30 min. After that,
sections were incubated for 1 h and 45 min
at room temperature and overnight at 4ºC in
the mixture solution containing the primary
antibodies: monoclonal anti-3-HAA or anti-
KYNA antibodies (diluted 1/1,000;
Gemacbio, Saint Jean d’Illac, France), poly-
clonal rabbit anti-glial fibrillary acidic pro-
tein (GFAP) antibody (1/100; Dako,
Glostrup, Denmark) or polyclonal goat anti-
ionized calcium-binding adapter molecule 1
(IBA-1) antibody (1/1,500, Abcam,
Cambridge, UK). Afterward, three washes
were conducted in PBS for 30 min at room
temperature. Then, sections were incubated
with the corresponding biotinylated anti-
mouse/goat/rabbit immunogammaglobulin
(BA-1,000; BA-5,000; BA-9,200, Vector
Labs, Burlingame, CA, USA) (1/200 in
mixture solution) for 1 h at room tempera-
ture. Later, sections were washed three
times with PBS for 30 min and incubated
with the avidin-biotin-peroxidase complex
(ABC, Vectastain PK-6,100) (1/100) for 1 h
at room temperature. Then, sections were
rinsed three times with PBS for 30 min, and
a later wash of at least 10 min in Tris-HCl
buffer. Finally, during 10 min in darkness
and room temperature, the peroxidase was
developed with H2O2, and 3, 3’ diaminoben-
zidine (chromogen).
The immunological characteristics of
the primary antibodies (anti-KYNA, anti-3-
HAA) used here have been published previ-
ously.8-10 In order to confirm the specificity
of the immunoreactivity observed here, the
following histological controls were also
conducted: i) omission of the primary
and/or secondary antibodies, and ii) pre-
absorption of the anti-KYNA or anti-3-
HAA antibodies with an excess (100
μg/mL) of their corresponding antigens
(KYNA or 3-HAA). In both cases no resid-
ual immunoreactivity was found. The speci-
ficity of the anti-IBA-1 antibody has been
previously demonstrated9 and, here, the
immunoreactivity also disappeared after its
preabsorption with the corresponding anti-
gen. Moreover, in order to demonstrate that
the immunoreactivity found for KYNA and
3-HAA was located in astrocytes, a double-
labelling was conducted in sections previ-
ously developed with DAB (brown precipi-
tate) for KYNA or 3-HAA. We followed a
previous published protocol.8-10 Thus, 4-
chloro-1-naphol was used to show the pres-
ence of GFAP (blue precipitate) in those
cells containing KYNA or 3-HAA and the
immunocytochemistry procedure showed
that double-labelling cells (GFAP-KYNA
or GFAP-3-HAA) were astrocytes.
Finally, the stereotaxic atlas of Paxinos
and Watson32 was used for nomenclature
and mapping. Photomicrographs were
obtained by using a Kyowa Unilux-12
microscope coupled to an Olympus DP50
digital camera. Only the brightness and
contrast of the images were adjusted in
order to improve the visualization of




In all animals of the operated group
(surgical procedure with ablation of the
motor cortex), the results found were iden-
tical, independently of the date in which rats
were perfused (17, 30 or 54 days after the
ablation). In all animals of the sham-operat-
ed group (surgical procedure without abla-
tion of the cortex), the results observed
were also identical, independently of the
perfusion date. However, these results were
very different when comparing sham-oper-
ated and operated animals (Table 1). In both
groups, four markers have been studied:
KYNA and 3-HAA (to demonstrate the
involvement of the IDO pathway), IBA-1(to
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Figure 1. Low-power magnifications of brains after fixation. A) Sham operated animal;
B) operated animal; the arrow indicates the lesion conducted on the motor cortex.
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check microglia activation) and GFAP (to
confirm the presence of KYNA and 3-HAA
in astrocytes).
Sham-operated animals
No immunolabelling was observed for
KYNA and 3-HAA (Table 1), whereas a
normal distribution of microglia (immuno-
reactivity for IBA-1) and astrocytes
(immunoreactivity for GFAP) in both ipsi-
lateral and contralateral sides was visual-
ized (Table 1). Thus, after the surgical pro-
cedure without ablation of the motor cortex,
the expression of KYNA and 3-HAA was
not observed.
Operated animals
In the ipsilateral side, KYNA and 3-
HAA were exclusively observed in the
region around the ablated area and in the
motor cortex white matter placed close to
the injured region. A high immunoreactiv-
ity (overexpression) for KYNA (Figure 2
and Figure 3 A,B) and 3-HAA (Figure 3
C,D and Figure 4) was found around this
region, but the number of immunoreactive
cells decreased moving away from the
injured region (in fact, immunoreactivity
disappeared in the regions of the white
matter located far from the lesion) (Figure
2A and Figure 4A). Thus, a higher number
of immunoreactive cells (containing
KYNA or 3-HAA) was observed close to
the lesion. In the white matter of the con-
tralateral side, some cells containing
KYNA or 3-HAA were also observed
(Table 1). In comparison with sham-oper-
ated animals, an overexpression of the four
markers studied (there is a perfect match
between them) was observed in the region
around the ablation (ipsilateral side) (Table 1)
(Figures 2, 4, 5). As KYNA and 3-HAA,
the expression of IBA-1 and GFAP
decreased moving away from the region
surrounding the lesion. In the white matter
of the motor cortex placed far from the
injured region, the expression of IBA-1 or
GFAP was similar (normal distribution) to
that found in the contralateral side of the
operated animals and in sham-operated
animals (Table 1).
Astrocytes: Coexistence of GFAP
with KYNA or 3-HAA 
Cells containing GFAP, KYNA or 3-
HAA showed the same morphological char-
acteristics (Figures 2-4). In order to confirm
the presence of KYNA and 3-HAA in astro-
cytes (GFAP), a double-immunolabelling
technique was applied and GFAP-
immunoreactivity was detected in astro-
cytes expressing KYNA or 3-HAA (Figure
3). The coexistence was observed in both
ipsilateral and contralateral sides (operated
animals).
Discussion  
Here, it has been demonstrated for the
first time that KYNA and 3-HAA were
exclusively found in astrocytes of animals
in which the ablation of the motor cortex
was performed and that both molecules
were overexpressed around the injured
region. Moreover, the results observed (dis-
tribution/degree of the immunoreactivity)
were identical in animals perfused 17, 30 or
54 days after the ablation.   
Anti-KYNA and anti-3-HAA
labelling
As previously described,8,10 monoclonal
anti-KYNA and 3-HAA antibodies have
been fully characterized by ELISA. Both
antibodies were considered of high affinity
(10-10 M for KYNA; 10-9 M for 3-HAA) and
highly specifics, since they do not cross-
react with close chemical structures.8,10
After the preabsorption of these antibodies
with their corresponding antigens (anti-
KYNA with KYNA, anti-3-HAA with 3-
HAA) the immunoreactivity disappeared
completely demonstrating that the immuno-
labelling observed was specific of the tar-
geted molecules. Moreover, here, a double
immunolabelling technique has been
applied to demonstrate in astrocytes the
coexistence of GFAP and KYNA or 3-
HAA.8-10,33 4-chloro-1-napthol was used to
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Figure 2. Immunoreactivity for KYNA. Ipsilateral side of the ablated motor cortex (A-D).
A) Note the expression of KYNA in the region close to the lesion; the number of
immunoreactive cells decreased moving away from the injured region. The region delim-
ited by a rectangle is shown, at a higher magnification, in panel C. B) Picture of another
region showing the immunoreactivity all around the lesion; C) The rectangle in the upper
right corner is a higher magnification of the small left rectangle. D) High power magni-
fication image, note the morphology of the cells containing KYNA. Small arrow D, dorsal
orientation.
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Table 1. Immunolabelling for kynurenic acid, 3-hydroxyanthranilic, ionized calcium-
binding adapter molecule 1 and glial fibrillary acidic protein. 
Marker                         Sham-operated     Operated
                                                    Ipsilateral     Contralateral   Ipsilateral     Contralateral
Kynurenic acid                                                    -                                -                         +++                          +* 
3-hydroxyanthranilic                                          -                                -                         +++                          +*
Ionized calcium-binding                                 +                              +                        +++                           +
adapter molecule 1                                            
Glial fibrillary acidic protein                          +                              +                        +++                           +
-, absence of immunoreactivity; +, presence; +*, only observed in some astrocytes located in the white matter of the motor cortex;
+++, very high: region around the ablation.










show GFAP immunoreactivity in those sec-
tions in which the presence of KYNA or 3-
HAA had been observed by using
diaminobenzidine. It is known that the
diaminobenzidine reaction masks the anti-
gen and catalytic sites of the first sequence
of the immunoreagents, preventing an inter-
action of the second sequence with the
reagents.8-10,33 Thus, in a neurotrauma model
and thanks to the use of specific antibodies,
it has been visualized for the first time the
presence of KYNA and 3-HAA in rat astro-
cytes. This means that the IDO pathway is
involved in the mechanisms occurring in
brain trauma.
Trauma versus transient middle
cerebral artery occlusion 
Expression of KYNA and 3-HAA
(peripheral area of the injured region and in
the white matter of the ipsilateral and con-
tralateral sides) occurred from at least 17
days after the ablation procedure. From
early phases of stroke, it has been also
described the expression of both
molecules.8,10 Thus, in the transient middle
cerebral artery occlusion model (tMCAO,
stroke model), the expression of KYNA and
3-HAA was exclusively found around the
infarcted region.8,10 However, in the trauma
model, KYNA and 3-HAA were found
around the injured region (there was a per-
fect anatomical match between both mole-
cules) but also in astrocytes placed in the
white matter of the ipsilateral and contralat-
eral hemispheres. The immunolabelling
found in the contralateral side was visual-
ized only in a few cells. The presence of
astrocytes (containing KYNA or 3-HAA) in
the white matter could be due to a possible
involvement of both molecules in mecha-
nisms of neurogenesis and new axonal con-
nections occurring after cortical ablation.29
The presence of KYNA and 3-HAA in the
contralateral hemisphere supports the
involvement of these molecules in the com-
pensation mechanisms developed after a
motor cortex injury. In a stroke model, it has
been reported that sprouting neurons have
many genes activated which are linked to
axonal pathfinding or sprouting.34 This
pathfinding processes are in close associa-
tion with astrocytes and surrounding
milieu.35-37 Thus, the role of the IDO path-
way molecules (KYNA, 3-HAA) in the pre-
vious mentioned processes should be stud-
ied in-depth since it seems that this pathway
plays an important role in the pathological
processes involved in brain injury and
repair.
In the neurotrauma model, the overex-
pression of KYNA, 3-HAA, IBA-1 and
GFAP was observed around of the ablated
cortex; this is in agreement with the results
found in the tMCAO model in which a per-
                                                                                                        Original Paper
Figure 3. Photographs taken from the region around the lesion. Double-labelling of
astrocytes containing GFAP and KYNA (A, B) or GFAP and 3-HAA (C, D). The immuno-
labelling for GFAP appears in blue (chloronapthol) and that of KYNA or 3-HAA in
brown (diaminobenzidine). Note the blue staining in the astrocyte projections (arrow-
heads) and the brown staining in the cell bodies. Small arrow D, dorsal orientation.
Figure 4. Immunoreactivity for 3-HAA. Ipsilateral side of the motor cortex. A) Note the
expression of 3-HAA in the region close to the lesion; the number of immunoreactive cells
decreased moving away from the injured region; the region delimited by the upper rec-
tangle is shown at higher magnification in panel B, and that of the lower rectangle in
panel C. B) High-power magnification of the region delimited by the left rectangle is
shown in panel D; right rectangle: a detail of another region showing immunoreactive
cells. D) Rectangle, detail of cells containing 3-HAA. Small arrow V, ventral orientation.  
[European Journal of Histochemistry 2018; 62:2985] [page 281]










fect match of the four markers was also
found in the ischemic area. Moreover, as
previously described in the tMCAO
model,8-10 here in astrocytes, it has been also
demonstrated the coexistence GFAP and
KYNA or 3-HAA.
In the tMCAO model, a great variability
in the extension of the infarcted region has
been reported,9,38 but in the neurotrauma
model this great variability does not occur
because the extension of the injured region
is almost always the same. This does not
occur because of the stereotaxic apparatus
used when conducting the ablation; thus,
the variability in the extension of the
mechanical lesion is very limited in com-
parison to that observed in stroke. 
2,3 indoleamine dioxygenase pathway 
Both IDO pathway markers (KYNA and
3-HAA) have been found from 17 days after
the surgical procedure to late phases (54 days
after ablation). This pathway plays an impor-
tant role in the immune response39-41 and
alterations of this pathway in several diseases
(stroke, multiple sclerosis, Parkinson,
Alzheimer, schizophrenia) have been report-
ed.18,21,42,43
In the IDO pathway, KYNA and 3-HAA
are products of the catabolism of tryptophan
and it is known that they exert opposite
actions: KYNA is a neuroprotector and 3-
HAA (a free radical generator) a cytotox-
ic.9,21,43-48 In the neurotrauma model used
here, the expression of catabolites (KYNA,
3-HAA) of the IDO pathway is in agree-
ment with the data reported in the tMCAO
model.8-10 In the latter model, it is known
that the administration of a new drug candi-
date (GEMST) reverted the expression of
both KYNA and 3-HAA.9 Thus, based on
the opposed exerted effects of both mole-
cules, a mechanism directed to counterbal-
ance the cytotoxic effect of the 3-HAA by
an expression of KYNA could occur in both
models (stroke, brain trauma). Moreover,
KYNA acts as a glutamate receptor antago-
nist9 and hence the overexpression of
KYNA in the neurotrauma model could
block the deleterious actions exerted by glu-
tamate. Our data also suggest that, after a
brain injury, the enzymes kynureninase and
microsomal hydroxylase (involved in the
synthesis of 3-HAA) and kynurenine
aminotransferases (involved in the synthe-
sis of KYNA) are up-regulated in astro-
cytes. In the future, the inhibitors/activators
of these enzymes might be investigated. It is
also important to note that 3-HAA is an
intermediary metabolite of the quinolinic
acid, which is much more cytotoxic than 3-
HAA.47,49 Quinolinic acid induces the dam-
age/death of glia cells and neurons and it is
known that inhibitors of the enzyme 3-HAA
oxidase (involved in the synthesis of quino-
linic acid from 3-HAA) decreased the tissue
damage promoted by the quinolinic acid.10
Therefore, after the ablation of the cortex an
augmentation of the level of quinolinic acid
could occur as it has been previously report-
ed after spinal cord injury.50 Because of the
intrinsic toxicity of quinolinic acid, in the
future this point must be studied in-depth.
Our findings are in agreement with pre-
vious works.51-53 In the present study and in
the tMCAO model,8,9 we have suggested
that KYNA acts as a neuroprotector. In
rodents, it has been reported that KYNA
and kynurenate (a salt or ester of KYNA
and an excitatory amino acid receptor
antagonist) also exerted beneficial
effects.51,53 In this sense, it is known that
after a traumatic brain injury, the kynure-
nate decreased edema formation, improved
motor deficits and attenuated the trauma-
induced cognitive dysfunction51 and that,
before performing a traumatic brain injury,
the in situ administration of KYNA attenu-
ated rapid astroglial and microglial respons-
es.53 It is known that, after a traumatic brain
injury, a rapid response of both astrocytes
and microglia occurred.53 Moreover, the
results found here, in a rat traumatic brain
injury model, are in agreement with those
observed in humans, since after a traumatic
brain injury the levels of both KYNA and
quinolinic acid increased in the human cere-
brospinal fluid.52 In schizophrenic patients,
an increase in the levels of KYNA and
picolinic acid has been also reported.54 In
the latter case, the concentrations of both
metabolites decreased when memantine (a
non-competitive NMDA receptor antago-
nist) and galantamine (an acetyl-
cholinesterase inhibitor and a modulator of
the alpha-7 nicotinic acetylcholine receptor)
were co-administered.54 This co-administra-
tion also improved cognition.54,55 It is
important to note that, in the tMCAO
model,9 the administration of GEMST also
decreased the expression of both KYNA
and 3-HAA. This could also occur in the
traumatic brain injury model. Finally, it has
been reported that mismatch negativity is
generated automatically in patients with
traumatic brain injury56 and that, in schizo-
phrenic patients, the administration of N-
acetylcysteine (a glutathione precursor and
antioxidant) improved mismatch negativity
and protected the integrity of the white mat-
ter.57,58 In the future, the action of GEMST
on the mismatch negativity/white matter
should be investigated. In this sense, it has
been demonstrated that GEMSP (a GEMST
analogue and a safe and well-tolerated drug
candidate against multiple sclerosis) exert-
ed a myelin-protecting role.59
In summary, in a neurotrauma model
(ablation of the frontal motor cortex): i) it
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Figure 5. Immunoreactivity for IBA-1. A) High density of immunoreactive cells around
the injured region. B) High-power magnification of the region delimited by the rectangle
in A. C) Representative image of the labeling with IBA-1 observed in the contralateral
side of the motor cortex or in sham-operated animals; compare the immunolabelling
appearing in A and B. D) Control: absence of labelling when the first antibody was omit-
ted in the immunocytochemical technique. Small arrow D, dorsal orientation.
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has been demonstrated the presence of
astrocytes containing KYNA or 3-HAA; ii)
KYNA and 3-HAA were exclusively found
(overexpression) in the region around the
ablation and in the white matter of both ipsi-
lateral and contralateral sides; iii) there is a
perfect match between KYNA and 3-HAA;
the region around the ablation is also char-
acterized by the overexpression of GFAP
and IBA-1; iv) KYNA and 3-HAA are
expressed from mild phases (17 days after
the surgical procedure) to 54 days after
ablation; v) the neuroprotective metabolite
KYNA could be overexpressed in order to
counterbalance the cytotoxic effect of 3-
HAA and its product (quinolinic acid), and
vi) the presence of astrocytes containing
KYNA and 3-HAA in the contralateral
hemisphere means that they could be
involved in the pathfinding and/or compen-
sation mechanisms occurring after the abla-
tion of the motor cortex. Finally, a suitable
future experimentation could be the treat-
ment of ablated animals with GEMST, a
drug candidate for the treatment of stroke,
since GEMST reverted the neuroanatomical
changes (diminished the overexpression of
KYNA, 3-HAA, IBA-1 and GFAP and
exerted a general beneficial action) induced
by an ischemic insult.
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